Banques de tissus : Questions médicales fréquentes
Nom anglais: Tissue Banks
Descriptor UI:D014015
Tree Number:N02.278.065.900
Termes MeSH sélectionnés :
Molecular Docking Simulation
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Banques de tissus : Questions médicales les plus fréquentes",
"headline": "Banques de tissus : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Banques de tissus : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-22",
"dateModified": "2025-04-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Banques de tissus"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Biobanques",
"url": "https://questionsmedicales.fr/mesh/D018070",
"about": {
"@type": "MedicalCondition",
"name": "Biobanques",
"code": {
"@type": "MedicalCode",
"code": "D018070",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N02.278.065"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Banques d'os",
"alternateName": "Bone Banks",
"url": "https://questionsmedicales.fr/mesh/D018586",
"about": {
"@type": "MedicalCondition",
"name": "Banques d'os",
"code": {
"@type": "MedicalCode",
"code": "D018586",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N02.278.065.900.205"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Banques des yeux",
"alternateName": "Eye Banks",
"url": "https://questionsmedicales.fr/mesh/D005125",
"about": {
"@type": "MedicalCondition",
"name": "Banques des yeux",
"code": {
"@type": "MedicalCode",
"code": "D005125",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N02.278.065.900.400"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Banques de tissus",
"alternateName": "Tissue Banks",
"code": {
"@type": "MedicalCode",
"code": "D014015",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Victoria Stadler Tasca Ribeiro",
"url": "https://questionsmedicales.fr/author/Victoria%20Stadler%20Tasca%20Ribeiro",
"affiliation": {
"@type": "Organization",
"name": "Division of Infectious Diseases, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil."
}
},
{
"@type": "Person",
"name": "Luciana Cristina Wollmann",
"url": "https://questionsmedicales.fr/author/Luciana%20Cristina%20Wollmann",
"affiliation": {
"@type": "Organization",
"name": "Human Tissues Bank, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil."
}
},
{
"@type": "Person",
"name": "Paula Hansen Suss",
"url": "https://questionsmedicales.fr/author/Paula%20Hansen%20Suss",
"affiliation": {
"@type": "Organization",
"name": "Division of Infectious Diseases, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil."
}
},
{
"@type": "Person",
"name": "Felipe Francisco Tuon",
"url": "https://questionsmedicales.fr/author/Felipe%20Francisco%20Tuon",
"affiliation": {
"@type": "Organization",
"name": "Division of Infectious Diseases, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil. felipe.tuon@pucpr.br."
}
},
{
"@type": "Person",
"name": "Giulia Montagner",
"url": "https://questionsmedicales.fr/author/Giulia%20Montagner",
"affiliation": {
"@type": "Organization",
"name": "Fondazione Banca dei Tessuti del Veneto (FBTV), 31100 Treviso, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Molecular docking, simulation and binding free energy analysis of small molecules as PfHT1 inhibitors.",
"datePublished": "2022-08-26",
"url": "https://questionsmedicales.fr/article/36026508",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0268269"
}
},
{
"@type": "ScholarlyArticle",
"name": "Py-CoMFA, docking, and molecular dynamics simulations of Leishmania (L.) amazonensis arginase inhibitors.",
"datePublished": "2024-05-21",
"url": "https://questionsmedicales.fr/article/38773273",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-62520-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Exploring the molecular mechanism of ginseng against anthracycline-induced cardiotoxicity based on network pharmacology, molecular docking and molecular dynamics simulation.",
"datePublished": "2024-09-06",
"url": "https://questionsmedicales.fr/article/39243097",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s41065-024-00334-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Study of the antidiabetic mechanism of berberine compound on FOXO1 transcription factor through molecular docking and molecular dynamics simulations.",
"datePublished": "2024-07-09",
"url": "https://questionsmedicales.fr/article/38981921",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00894-024-06060-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Research advances of molecular docking and molecular dynamic simulation in recognizing interaction between muscle proteins and exogenous additives.",
"datePublished": "2023-07-08",
"url": "https://questionsmedicales.fr/article/37453331",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.foodchem.2023.136836"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Établissements, main d'oeuvre et services de soins de santé",
"item": "https://questionsmedicales.fr/mesh/D005159"
},
{
"@type": "ListItem",
"position": 3,
"name": "Établissements de santé",
"item": "https://questionsmedicales.fr/mesh/D006268"
},
{
"@type": "ListItem",
"position": 4,
"name": "Biobanques",
"item": "https://questionsmedicales.fr/mesh/D018070"
},
{
"@type": "ListItem",
"position": 5,
"name": "Banques de tissus",
"item": "https://questionsmedicales.fr/mesh/D014015"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Banques de tissus - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Banques de tissus",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Banques de tissus",
"description": "Comment sont diagnostiquées les maladies nécessitant des tissus ?\nQuels tests sont utilisés pour évaluer la qualité des tissus ?\nLes banques de tissus effectuent-elles des diagnostics ?\nQuels critères sont utilisés pour sélectionner les tissus ?\nComment les tissus sont-ils prélevés pour analyse ?",
"url": "https://questionsmedicales.fr/mesh/D014015?mesh_terms=Molecular+Docking+Simulation&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Banques de tissus",
"description": "Quels symptômes peuvent indiquer un besoin de greffe de tissu ?\nLes maladies liées aux tissus présentent-elles des symptômes spécifiques ?\nComment les symptômes influencent-ils le choix des tissus ?\nLes symptômes peuvent-ils varier selon le donneur de tissu ?\nQuels symptômes sont associés aux rejets de greffe ?",
"url": "https://questionsmedicales.fr/mesh/D014015?mesh_terms=Molecular+Docking+Simulation&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Banques de tissus",
"description": "Comment prévenir les infections lors de greffes ?\nQuelles mesures sont prises pour éviter le rejet ?\nLes banques de tissus effectuent-elles des tests de dépistage ?\nComment sensibiliser le public sur le don de tissus ?\nQuelles sont les recommandations pour les donneurs potentiels ?",
"url": "https://questionsmedicales.fr/mesh/D014015?mesh_terms=Molecular+Docking+Simulation&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Banques de tissus",
"description": "Quels traitements utilisent des tissus de banques ?\nComment les tissus sont-ils préparés pour les traitements ?\nLes banques de tissus participent-elles à la recherche ?\nQuels sont les risques associés aux traitements par greffe ?\nLes traitements par tissus sont-ils toujours efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D014015?mesh_terms=Molecular+Docking+Simulation&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Banques de tissus",
"description": "Quelles complications peuvent survenir après une greffe ?\nComment gérer les complications post-greffe ?\nLes complications varient-elles selon le type de tissu ?\nQuels signes indiquent une complication après greffe ?\nLes complications peuvent-elles être évitées ?",
"url": "https://questionsmedicales.fr/mesh/D014015?mesh_terms=Molecular+Docking+Simulation&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Banques de tissus",
"description": "Quels facteurs augmentent le risque de rejet ?\nLe tabagisme influence-t-il le succès des greffes ?\nComment l'âge affecte-t-il le don de tissus ?\nLes antécédents médicaux influencent-ils le don de tissus ?\nQuels comportements à risque affectent le don de tissus ?",
"url": "https://questionsmedicales.fr/mesh/D014015?mesh_terms=Molecular+Docking+Simulation&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment sont diagnostiquées les maladies nécessitant des tissus ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les maladies sont diagnostiquées par des examens cliniques, imageries et analyses de tissus."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la qualité des tissus ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests histologiques et microbiologiques sont effectués pour évaluer la qualité."
}
},
{
"@type": "Question",
"name": "Les banques de tissus effectuent-elles des diagnostics ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles ne diagnostiquent pas, mais fournissent des tissus pour des diagnostics."
}
},
{
"@type": "Question",
"name": "Quels critères sont utilisés pour sélectionner les tissus ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tissus sont sélectionnés selon des critères de qualité, d'origine et d'usage prévu."
}
},
{
"@type": "Question",
"name": "Comment les tissus sont-ils prélevés pour analyse ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tissus sont prélevés par biopsie ou lors de chirurgies, sous conditions stériles."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un besoin de greffe de tissu ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la douleur chronique ou la défaillance d'organe peuvent indiquer ce besoin."
}
},
{
"@type": "Question",
"name": "Les maladies liées aux tissus présentent-elles des symptômes spécifiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, chaque maladie peut avoir des symptômes spécifiques selon le type de tissu affecté."
}
},
{
"@type": "Question",
"name": "Comment les symptômes influencent-ils le choix des tissus ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes aident à déterminer le type de tissu nécessaire pour le traitement approprié."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils varier selon le donneur de tissu ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de l'état de santé du donneur et de son historique."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés aux rejets de greffe ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la douleur, la fièvre et l'inflammation peuvent indiquer un rejet."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections lors de greffes ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des protocoles stricts de stérilisation et de suivi post-greffe sont essentiels."
}
},
{
"@type": "Question",
"name": "Quelles mesures sont prises pour éviter le rejet ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des immunosuppresseurs sont administrés pour réduire le risque de rejet après greffe."
}
},
{
"@type": "Question",
"name": "Les banques de tissus effectuent-elles des tests de dépistage ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles effectuent des tests pour dépister les maladies transmissibles chez les donneurs."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser le public sur le don de tissus ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des campagnes d'information et d'éducation sont menées pour encourager le don de tissus."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations pour les donneurs potentiels ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les donneurs doivent être en bonne santé et respecter les critères d'éligibilité établis."
}
},
{
"@type": "Question",
"name": "Quels traitements utilisent des tissus de banques ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les greffes de peau, de cornée et d'organes utilisent des tissus provenant de banques."
}
},
{
"@type": "Question",
"name": "Comment les tissus sont-ils préparés pour les traitements ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tissus sont stérilisés, conservés et parfois modifiés pour s'adapter aux traitements."
}
},
{
"@type": "Question",
"name": "Les banques de tissus participent-elles à la recherche ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles fournissent des tissus pour la recherche sur les maladies et les traitements."
}
},
{
"@type": "Question",
"name": "Quels sont les risques associés aux traitements par greffe ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent le rejet, les infections et les complications liées à l'anesthésie."
}
},
{
"@type": "Question",
"name": "Les traitements par tissus sont-ils toujours efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité dépend de nombreux facteurs, y compris la compatibilité et l'état du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après une greffe ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent le rejet, les infections et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications post-greffe ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et des traitements appropriés sont nécessaires pour gérer les complications."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le type de tissu ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent varier selon le type de tissu greffé et l'état du patient."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication après greffe ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme la douleur accrue, la fièvre ou l'inflammation peuvent indiquer une complication."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par une bonne préparation et un suivi rigoureux."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de rejet ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent la compatibilité tissulaire, l'âge et l'état de santé général du patient."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le succès des greffes ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut compromettre la guérison et augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Comment l'âge affecte-t-il le don de tissus ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge peut influencer la qualité des tissus et la décision d'accepter un don."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le don de tissus ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies transmissibles peuvent rendre un donneur inéligible."
}
},
{
"@type": "Question",
"name": "Quels comportements à risque affectent le don de tissus ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des comportements comme l'usage de drogues ou des relations sexuelles non protégées peuvent affecter l'éligibilité."
}
}
]
}
]
}
Antimalarial drug resistance has thrown a spanner in the works of malaria elimination. New drugs are required for ancillary support of existing malaria control efforts. Plasmodium falciparum requires ...
Leishmaniasis is a disease caused by a protozoan of the genus Leishmania, affecting millions of people, mainly in tropical countries, due to poor social conditions and low economic development. First-...
Previous clinical and basic studies have revealed that ginseng might have cardioprotective properties against anthracycline-induced cardiotoxicity (AIC). However, the underlying mechanism of ginseng a...
Fourteen drug-disease common targets were identified. Enrichment analysis showed that the AGE-RAGE in diabetic complications, fluid shear stress and atherosclerosis, and TNF signaling pathway were pot...
This study suggested that ginseng might exert their protective effects against AIC through the derived effector compounds beta-Sitosterol, Kaempferol and Fumarine by targeting CCNA2, STAT1, and ICAM1,...
Diabetes mellitus (DM) is a metabolic disorder disease that causes hyperglycemia conditions and associated with various chronic complications leading to mortality. Due to high toxicity of conventional...
Docking between ligand and FOXO1 receptor was carried out with Autodock4.2. For molecular dynamics simulations, the force fields of DNA.OL15, protein.ff14SB, gaff2, and tip3p were used....
During storage and processing, muscle proteins, e.g. myosin and myoglobin, will inevitably undergo degeneration, which is thus accompanied by quality deterioration of muscle foods. Some exogenous addi...
Cereblon (CRBN) is a substrate receptor of E3 ubiquitin ligase as well as the target of thalidomide and lenalidomide, plays a vital role in endogenous protein degradation. In this article, two series ...
Direct oral anticoagulants are an important and relatively new class of synthetic anticoagulant drugs commonly used for the pharmacotherapy of thromboembolic disorders. However, they still have some l...
Cancer is a serious threat to human life and social development and the use of scientific methods for cancer prevention and control is necessary. In this study, HQSAR, CoMFA, CoMSIA and TopomerCoMFA m...
The pandemic of COVID-19 caused by SARS-CoV-2 has made a worldwide health emergency. Despite the fact that current vaccines are readily available, several SARSCoV-2 variants affecting the existing vac...
Oritavancin is a semi-synthetic lipoglycopeptide antibiotic primarily used to treat serious infections caused by Gram-positive bacteria. The aim of this study was to elucidate possible molecular targe...
Computational methods were used in this study which include target prediction, molecular docking, molecular dynamics simulation, pharmacokinetics prediction, and physiological-based pharmacokinetics (...
Oritavancin was moderately soluble in water and did not permeate the blood-brain barrier. Seven molecular targets were identified in humans. Molecular docking results showed highest binding affinity o...
This comprehensive computational study has provided invaluable insights into the pharmacological profile of Oritavancin, aiding its further development and optimization for clinical use....